Willis Towers Watson (WTW)
(Delayed Data from NSDQ)
$280.42 USD
+0.54 (0.19%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $280.44 +0.02 (0.01%) 7:32 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
WTW 280.42 +0.54(0.19%)
Will WTW be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for WTW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WTW
Brown & Brown (BRO) Gains 40% YTD: Will the Rally Last?
Arthur J. Gallagher (AJG) Gains 25% YTD: More Upside Left?
WTW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Willis Towers Watson (WTW) is a Great Choice
Arthur J. Gallagher (AJG) Q2 Earnings Beat Estimates, Rise Y/Y
Willis Towers (WTW) Q2 Earnings Beat Estimates, Improve Y/Y
Other News for WTW
Willis Towers Watson (WTW) Receives a New Rating from Truist Financial
Maintaining Hold on Willis Towers Watson: A Balanced View Amid Medicare Revenue Challenges and Strategic Growth
Seth Klarman's Strategic Reduction in Theravance Biopharma Inc
Seth Klarman's Strategic Moves in Q2 2024: A Closer Look at Humana Inc's Prominent Position
Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2024 Update